These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9692133)

  • 1. Hypomagnesaemic tetany associated with repeated courses of intravenous tobramycin in a patient with cystic fibrosis.
    Adams JP; Conway SP; Wilson C
    Respir Med; 1998 Mar; 92(3):602-4. PubMed ID: 9692133
    [No Abstract]   [Full Text] [Related]  

  • 2. Tetany in a child with AIDS receiving intravenous tobramycin.
    Slayton W; Anstine D; Lakhdir F; Sleasman J; Neiberger R
    South Med J; 1996 Nov; 89(11):1108-10. PubMed ID: 8903300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypomagnesaemic tetany associated with prolonged treatment with aminoglycosides.
    Wilkinson R; Lucas GL; Heath DA; Franklin IM; Boughton BJ
    Br Med J (Clin Res Ed); 1986 Mar; 292(6523):818-9. PubMed ID: 3082455
    [No Abstract]   [Full Text] [Related]  

  • 4. The effects of intravenous tobramycin on renal tubular function in children with cystic fibrosis.
    Glass S; Plant ND; Spencer DA
    J Cyst Fibros; 2005 Dec; 4(4):221-5. PubMed ID: 16239129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aminoglycoside-associated hypomagnesaemia in children with cystic fibrosis.
    Akbar A; Rees JH; Nyamugunduru G; English MW; Spencer DA; Weller PH
    Acta Paediatr; 1999 Jul; 88(7):783-5. PubMed ID: 10447142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parenteral administration of tobramycin for pulmonary exacerbations in cystic fibrosis patients: toxicity, serum levels and efficacy.
    Braccini G; Lori I; Neri AS; Festini F; Pela I; Ciuti R; Boni V; Zavataro L; Braggion C; De Martino M; Taccetti G
    J Chemother; 2009 Feb; 21(1):101-4. PubMed ID: 19297282
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhaled tobramycin-associated hearing loss in an adolescent with renal failure.
    Patatanian L
    Pediatr Infect Dis J; 2006 Mar; 25(3):276-8. PubMed ID: 16511399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Case ∣ Metabolic alkalosis in a patient with cystic fibrosis.
    Geara AS; Parikh A; Rekhtman Y; Rao MK
    Kidney Int; 2012 Feb; 81(4):421-2. PubMed ID: 22289798
    [No Abstract]   [Full Text] [Related]  

  • 9. Tobramycin ototoxicity. Repeated courses of high dosage treatment in children with cystic fibrosis.
    Thomsen J; Friis B; Jensen K; Bak-Pedersen K; Larsen PK
    J Antimicrob Chemother; 1979 May; 5(3):257-60. PubMed ID: 479061
    [No Abstract]   [Full Text] [Related]  

  • 10. Measurement of urinary N-acetyl-b-D-glucosaminidase in adult patients with cystic fibrosis: before, during and after treatment with intravenous antibiotics.
    Etherington C; Bosomworth M; Clifton I; Peckham DG; Conway SP
    J Cyst Fibros; 2007 Jan; 6(1):67-73. PubMed ID: 16844430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Piperacillin-tazobactam versus cefepime incidence of acute kidney injury in combination with vancomycin and tobramycin in pediatric cystic fibrosis patients.
    LeCleir LK; Pettit RS
    Pediatr Pulmonol; 2017 Aug; 52(8):1000-1005. PubMed ID: 28440913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aminoglycoside ototoxicity.
    Zheng Y; Schachern PA; Sone M; Papapella MM
    Otol Neurotol; 2001 Mar; 22(2):266-8. PubMed ID: 11300281
    [No Abstract]   [Full Text] [Related]  

  • 13. Hypomagnesaemic tetany.
    Ramage IJ; Ray M; Paton RD; Logan RW; Beattie TJ
    J Clin Pathol; 1996 Apr; 49(4):343-4. PubMed ID: 8655714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetany associated with cis-platin.
    Stuart-Harris R; Ponder BA; Wrigley PF
    Lancet; 1980 Dec; 2(8207):1303. PubMed ID: 6108477
    [No Abstract]   [Full Text] [Related]  

  • 15. Recurrent hypomagnesemia with proton-pump inhibitor rechallenge.
    Quasdorff M; Mertens J; Dinter J; Steffen HM
    Ann Intern Med; 2011 Sep; 155(6):405-7. PubMed ID: 21930865
    [No Abstract]   [Full Text] [Related]  

  • 16. Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients.
    Mulheran M; Hyman-Taylor P; Tan KH; Lewis S; Stableforth D; Knox A; Smyth A
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2293-9. PubMed ID: 16801404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
    Al-Aloul M; Nazareth D; Walshaw M
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effect of chronic intravenous and inhaled nephrotoxic antibiotic treatment on the renal function of patients with cystic fibrosis.
    Florescu MC; Lyden E; Murphy PJ; Florescu DF; Fillaus J
    Hemodial Int; 2012 Jul; 16(3):414-9. PubMed ID: 22469183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tobramycin inhalation powder (Tobi Podhaler) for cystic fibrosis.
    Med Lett Drugs Ther; 2013 Jun; 55(1419):51-2. PubMed ID: 23797798
    [No Abstract]   [Full Text] [Related]  

  • 20. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial.
    Smyth A; Tan KH; Hyman-Taylor P; Mulheran M; Lewis S; Stableforth D; Prof Knox A;
    Lancet; 2005 Feb 12-18; 365(9459):573-8. PubMed ID: 15708100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.